

### 2024 PORTFOLIO MOMENTUM

- Broadview portfolio companies raised \$433M in 2024
- We are thrilled to have co-invested with top-tier syndicate partners in 2024, including 415 Capital, Advent Life Sciences, Arboretum Ventures, Dawn Biopharma, EQT, Forbion, Gilde Healthcare, Intuitive Ventures, Merieux Equity Partners, Norwest Partners, Novo Holdings, Omega Funds, Panakes Partners, Pivotal bioVenture Partners, SR One, Versant Ventures, and Wellington Partners
- The pipeline remained robust with more than 700 investment opportunities considered in 2024
- Most importantly, Broadview’s portfolio companies have touched the lives of more than 643,000 patients to date

### NEW INVESTMENTS

- **IsomAb**—Anti-VEGFA<sub>165</sub>b antibody for the treatment of peripheral artery disease
- **CorFlow**—Combination diagnostic and drug delivery platform for microvascular obstruction
- **Alveron Pharma**—Reversal agent for intracerebral hemorrhage
- **Mosanna Therapeutics**—Intranasal spray for obstructive sleep apnea
- **Relief Cardiovascular**—Renal vein unloading system for diuretic resistant heart failure

## LONGVIEW VENTURES


Longview Ventures continued a steady pace of investment activity in 2024, focusing on select Broadview clinical-stage opportunities as a complement to Broadview’s dedication to Seed and Series A financings.

### 2024 INVESTMENTS


- **AtaCor**—\$28M Series C towards temporary pacing FDA approval and ICD pivotal readiness
- **XII Medical**—\$45M Series B to fund the completion of a pilot study
- **Antag Therapeutics**—€80M Series A to fund Phase II PoC
- **Alleivant Medical**—\$91M Series 2 to fund a pivotal trial in HF<sub>rEF</sub>

**Our mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.**

**INVESTMENT DOLLARS LEVERAGED**  
 BROADVIEW AND LONGVIEW’S INVESTMENTS ARE LEVERAGED 17.1X BY CO-AND FOLLOW-ON INVESTMENTS, AND NON-DILUTIVE GRANT FUNDING



### INVESTMENTS BY INDICATION



## TALENT

**David Prim** was promoted to Principal at Broadview Ventures. David has played a key role in several medical device investments, including Puzzle Medical, CorFlow Therapeutics, and Relief Cardiovascular. He has partnered closely with these and other portfolio companies to help guide their operational and corporate development. In the Principal role, David will continue to expand his responsibility across the Broadview organization.



### MANAGEMENT

Christopher Colecchi  
*Managing Director*

Maria Berkman, MD  
Christopher de Souza, PhD  
Daniel Gottlieb  
Benjamin Kreitman  
Hewmun Lau  
David Milan, MD  
Khushbu Modi  
Nichole Neal  
Tom Needham  
David Prim, PhD  
Sunny Varshney, MD

### STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD  
Thomas Hughes, PhD  
Costantino Iadecola, PhD  
Joseph Loscalzo, MD, PhD  
Michael Mendelsohn, MD  
Eric Rose, MD  
Hugh Watkins, MD, PhD

### ADVISORS

Annabel Chen-Tournoux, MD  
Teo Dagi, MD  
Marc Semigran, MD  
Viviany Taqueti, MD, MPH



### MANAGEMENT

Maria Berkman, MD  
*Managing Director*

Christopher de Souza, PhD  
Daniel Gottlieb  
Benjamin Kreitman  
Hewmun Lau  
Khushbu Modi  
Nichole Neal  
Tom Needham  
David Prim, PhD  
Sunny Varshney, MD

### INVESTMENT ADVISORY COMMITTEE

Jan Garfinkle  
Terry McGuire  
Chris Mirabelli, PhD  
Eric Rose, MD

### Leducq Members

Martin Landaluce  
David Milan, MD  
David Tancredi, MD, PhD

# INVESTMENTS THROUGH 2024

Company	Technology/Therapy	Founders/Management
<b>2024</b>		
IsomAb	anti-VEGFA <sub>165</sub> b antibody for the treatment of PAD	Jackie Turnbull, Dave Bates, Paul Edwards
CorFlow	combination diagnostic and drug delivery platform for MVO	Paul Mead, Rob Schwartz, Martin Rothman
Alveron Pharma	reversal agent for intracerebral hemorrhage	Ben Nichols, Stephan Peters
Mosanna Therapeutics	intranasal spray for obstructive sleep apnea	David Weber, Jonathan Talbot, Sascha Oliver Bucher
Relief Cardiovascular	renal vein unloading system for diuretic resistant HF	Alexander Cooper, Brent Ratz, Arshad Quadri
<b>2022</b>		
Puzzle Medical	percutaneous heart pump for patients with advanced HF	Jade Doucet-Martineau, Gabriel Georges, Francois Trudeau
Nyra Medical	transcatheter implant to treat mitral valve regurgitation	Lori Chmura, Murali Padala, Eric Sarin
Cardiosense	noninvasive sensor and algorithms for heart failure management	Amit Gupta, Omer Inan, Mozziyar Etemadi, Andrew Carek
<b>2021</b>		
XII Medical	minimally-invasive technology to address obstructive sleep apnea	Garrett Schwab, Anthony Caparso
RapidPulse	aspiration system to treat acute ischemic stroke	Sean McBrayer, David Gill, Carlos Rivera
Comanche BioPharma	siRNA therapeutic for the treatment of preeclampsia	T. Scott Johnson, Mike Young, Craig Mello
<b>2020</b>		
Antag Therapeutics	GIPR antagonist for obesity	Joerg Moeller, Alexander Sparre-Ulrich, Jens Juul Holst
Basking Biosciences	reversible anti-vWF aptamer for acute ischemic stroke	Richard Shea, Shahid Nimjee, Bruce Sullenger
HAYA Therapeutics	ncRNA-targeting antifibrotic therapeutics for heart failure	Samir Ounzain, Daniel Blessing
<b>2019</b>		
Alleviant Medical	atrial shunt for the treatment of heart failure	Jacob Kriegel, Adam Berman, Mary Byron
Renovacor*	gene therapy for a rare, familial form of dilated cardiomyopathy	Maggie Cook, Arthur Feldman
CroiValve	percutaneously implanted device for tricuspid regurgitation	Lucy O'Keeffe, Martin Quinn
<b>2018</b>		
AtaCor Medical	leadless extravascular pacing and defibrillation systems	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Kantum Pharma	P2Y14 inhibitor for cardiac surgery-associated acute kidney injury	Sylvie Breton, Glenn Batchelder
<b>2017</b>		
NIDO Surgical*	device for epicardial ablation of ventricular tachycardia	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
Mellitus	novel biomarker for the screening and diagnosis of gestational diabetes	Jose Halperin, Michael Chorev
Adient	bioresorbable IVC filter for prevention of pulmonary embolism	Mitch Eggers, Joseph Steele
Vectorious*	direct left atrial pressure sensor	Oren Goldshtein, Eyal Orion
EP Sciences	novel defibrillation waveform to reduce pain associated with ICD therapies	Ron Berger, Howard Levin
<b>2016</b>		
FineHeart	fully implantable, miniaturized circulatory support device for HF	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois
Gila Therapeutics	topical lingual PYY agonist for treatment of obesity	Tom Vasicek, Rich Horan
Aeromics	small molecule for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson
<b>2015</b>		
Pulmokine*	small molecule for pulmonary artery hypertension	Larry Zisman, Shreefal Mehta
Lyra Therapeutics*	bioresorbable platform for multiple indications	Bob Langer, George Whitesides, Maria Palasis
Epirium (Cardero)	mitochondrial biogenesis platform technology	George Schreiner, Sundeep Dugar, Russell Cox

\* Exited

# INVESTMENTS THROUGH 2024

Company	Technology/Therapy	Founders/Management
<b>2014</b>		
ZZ Biotech	<i>mutant APC peptide therapeutic for stroke</i>	Berislav Zlokovic, Kent Pryor, Joseph Romano
Ischemia Care	<i>immune cell gene expression profile diagnostic for stroke</i>	Jeff June
Acesion Pharma	<i>Small molecule to treat chronic atrial fibrillation</i>	Ulrik Sørensen, Morten Grunnet, Anders Gaarsdal Holst
Aria CV	<i>device for pulmonary hypertension</i>	John Scandurra, Karl Vollmers, Dan Gladney
<b>2013</b>		
Zumbro Discovery	<i>peptide therapeutic for treatment of resistant hypertension</i>	John Burnett, Horng Chen
BioKier	<i>small molecule anti-diabetic treatment</i>	George Szewczyk, Roger Nolan
Remedy*	<i>small molecule for the treatment of central nervous system edema</i>	Sven Jacobson
GI Windows	<i>non-surgical approach to gastric bypass</i>	Chris Thompson, Marvin Ryou
<b>2012</b>		
VGS	<i>external support for saphenous vein grafts in CABG</i>	Eyal Orion
InfoBionic	<i>cloud-based remote monitoring platform for atrial fibrillation</i>	Jeremy Ruskin, Stuart Long
Herantis*	<i>VEGF based gene therapy for lymphedema</i>	Antti Vuolanto
Declimmune	<i>MAB for treatment of post MI and I/R injury</i>	Christopher Mirabelli, Walter Newman
<b>2011</b>		
Cardialen	<i>implantable cardioversion for the treatment of AF</i>	Igor Efimov, Jeff Peters
NuPulse	<i>counterpulsation device for the treatment of HF</i>	Valluvan Jeevanandam, Douglas Altschuler
Aggamin	<i>sFlt-1 apheresis treatment for preeclampsia</i>	Ravi Thadhani, Paul Kussie, Ananth Karumanchi
Provasculon*	<i>peptide therapeutics for treatment of MI and I/R injury</i>	Rich Lee, Roger Kitterman
Apama*	<i>novel ablation system for treatment of AF</i>	Amr Salahieh
<b>2010</b>		
Allosteros	<i>CaMKII inhibitors for HF and AF</i>	Howard Schulman, Mark Anderson
Intravascular Imaging	<i>NIRF device for intracoronary artery imaging</i>	Farouc Jaffer, Vasilis Ntziachristos
Capricor*	<i>allogeneic stem cell therapy after MI</i>	Eduardo and Linda Marbán
CellAegis	<i>remote ischemic conditioning for MI</i>	Andrew Redington, Chris Calderone
<b>2009</b>		
CardiAQ Valve*	<i>transcatheter mitral valve</i>	Brent Ratz, Arshad Quadri, Rob Michiels
VentriNova	<i>gene therapy for regeneration of cardiac tissue</i>	Hina Chaudhry
miRagen*	<i>microRNAs for cardiovascular and oncology indications</i>	Bruce Booth, Mike Bristow, Eric Olson

\* Exited